Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zenith HealthcareBOM:530665 -0.32%63 Interest Coverage is 81.50 as of Jun. 2026, which is 93% above its 10-year median of 42.12. GuruFocus rates BOM:530665 with a GF Score™ of 63/100 and a GF Value™ of ₹3.58 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 684 Drug Manufacturers companies, Zenith Healthcare ranks worse than 146198.68% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Zenith Healthcare's
Operating Income
for the
three
months ended in Jun. 2026 was ₹1.1 Mil. Zenith Healthcare's Interest Expense for the
three
months ended in Jun. 2026 was ₹-0.0 Mil.
Zenith Healthcare's interest coverage for the quarter that ended in Jun. 2026 was 81.50.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Zenith Healthcare's Interest Coverage or its related term are showing as below:
BOM:530665's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 13.815 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Zenith Healthcare Interest Coverage Related Terms
Zenith Healthcare Interest Coverage Historical Data
* Premium members only.
The historical data trend for Zenith Healthcare's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Zenith Healthcare's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenith Healthcare Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zenith Healthcare's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Zenith Healthcare's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zenith Healthcare (BOM:530665) has a Interest Coverage of 81.50 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Zenith Healthcare and its competitors. This is 93% above median its historical median of 42.12. According to the industry distribution chart, Zenith Healthcare ranks #999999 out of 684 companies in the Drug Manufacturers industry.
Is Zenith Healthcare's Interest Coverage too high?
Zenith Healthcare's current Interest Coverage of 81.50 is 93% above median its 10-year median of 42.12. The Drug Manufacturers industry median Interest Coverage is 13.82. Zenith Healthcare's value of 81.50 is 489.9% above this industry median. Based on the distribution chart, Zenith Healthcare ranks #999999 out of 684 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zenith Healthcare has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zenith Healthcare's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zenith Healthcare ranks #999999 out of 684 companies for Interest Coverage. This places Zenith Healthcare in the lower half of its industry. The industry median Interest Coverage is 13.82. Zenith Healthcare's value of 81.50 is 489.9% above this benchmark. While the company's 10-year median is 42.12 vs. the industry median of 13.82, Zenith Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 13.82, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenith Healthcare's current Interest Coverage of 81.50 is 489.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Zenith Healthcare and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 13.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenith Healthcare's current Interest Coverage is 81.50, which is 93% above median its own 10-year median of 42.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Zenith Healthcare (BOM:530665) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹3.58, compared to a current price of ₹3.09 — trading 13.7% below its estimated fair value. The current Interest Coverage is 81.50, which is 93% above median its 10-year median of 42.12 and 489.9% above the Drug Manufacturers industry median of 13.82. Zenith Healthcare's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Zenith Healthcare (BOM:530665), the current Interest Coverage is 81.50 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zenith Healthcare (BOM:530665) Overvalued in 2026?
Based on GuruFocus' analysis, Zenith Healthcare stock appears to be undervalued.
The current stock price of ₹3.09 is trading 13.7% below its estimated GF Value™ of ₹3.58.
GuruFocus considers Zenith Healthcare to be Modestly Undervalued.
Key valuation signals for BOM:530665:
Interest Coverage: 81.50 (93% above median its 10-year median of 42.12)
GF Value™: ₹3.58 vs. price of ₹3.09 (13.7% below fair value)
Industry Position: 489.9% above the Drug Manufacturers median (#999999 of 684)
No single metric tells the full story. See the BOM:530665 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zenith Healthcare Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and trading of pharmaceutical formulations. The company also undertakes contracts for manufacturing business. It manufactures pharmaceutical formulations in the form of Tablets, Capsules, Oral liquids, and injectables. The company sells its products in India and also exports internationally.
63GF Score
Get the complete analysis for BOM:530665
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530665 has been successfully added to your 
